Xeris Pharma Reaches Deal With Tetris Pharma To Commercialize Ogluo In Europe

(RTTNews) - Xeris Pharmaceuticals Inc. (XERS) said that it has reached an agreement with Tetris Pharma Limited for the commercialization of Ogluo in the European Economic Area, United Kingdom, and Switzerland for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

As per the terms of the applicable agreements, Xeris will be responsible for product supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.

Xeris will receive up to $71 million in payments tied to the first commercial sale and other time-, launch- and sales-related milestones and collect a royalty on net sales.